Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Now Rated “Hold” by Wall Street Brokerages

Posted by Brian Himes on Oct 6th, 2026

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) have earned an average rating of “Hold” from the fourteen research firms that are presently covering the stock, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $108.11.

LNTH has been the subject of a number of research reports. B. Riley Financial downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. TD Cowen cut Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the stock from $110.00 to $102.50 in a research report on Monday, August 3rd. CJS Securities downgraded Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and reduced their price objective for the company from $125.00 to $102.50 in a research report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 target price on Lantheus in a research report on Monday, August 3rd.

Check Out Our Latest Research Report on LNTH

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Reinhart Partners LLC. lifted its holdings in Lantheus by 2.2% in the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the period. Legal & General Group Plc bought a new stake in shares of Lantheus during the 2nd quarter worth about $9,786,000. Carmignac Gestion lifted its stake in shares of Lantheus by 0.9% in the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock worth $148,671,000 after acquiring an additional 12,100 shares during the period. Epoch Investment Partners Inc. boosted its holdings in shares of Lantheus by 59.4% in the first quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock valued at $49,284,000 after acquiring an additional 242,222 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after acquiring an additional 582,661 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Trading Up 0.2%

Lantheus stock opened at $100.19 on Thursday. Lantheus has a 1 year low of $49.67 and a 1 year high of $111.86. The firm’s 50-day moving average is $100.55 and its 200-day moving average is $96.38. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company has a market cap of $6.54 billion, a P/E ratio of 24.20 and a beta of -0.06.

Lantheus (NASDAQ:LNTH – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.57 EPS. On average, equities analysts expect that Lantheus will post 4.5 earnings per share for the current year.

Lantheus Company Profile

(Get Free Report)

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.